The National Data Bank for rheumatic diseases: A multi-registry rheumatic disease data bank

Rheumatology

Volumn 50, Issue 1, 2011, Pages 16-24

  Wolfe, Frederick ^a   Michaud, Kaleb ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Data Bank; National Data Bank for rheumatic diseases; NDB; Registry

Indexed keywords

COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE REGISTRY; HUMAN; MEDICAL RESEARCH; NATIONAL PRACTITIONER DATA BANK; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; REVIEW; RHEUMATIC DISEASE;

ANTIRHEUMATIC AGENTS; BIOMEDICAL RESEARCH; DATABASES, FACTUAL; FEMALE; HEALTH STATUS; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; REGISTRIES; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 79951718504     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq155     Document Type: Review

References (50)

1. Stata Corporation. Stata Statistical Software: Release 11.0. College Station, TX: Stata Corporation, 2009.
2. Vergouwe Y, Royston P, Moons KG, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol 2010;63:205-14.
3. Royston P. Multiple imputation of missing values. Stata J 2004;4:227-41.
4. Twisk J, de Vente W. Attrition in longitudinal studies. How to deal with missing data. J Clin Epidemiol 2002;55: 329-37.
5. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology 2006;45:1370-5.
6. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010 (in press).
7. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
8. Fewell Z, Hernan MA, Wolfe F, Tilling H, Choi HK, Sterne AC. Controlling for time-dependent confounding using marginal structural models. Stata J 2004;4:402-20.
9. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004;31:1896-902.
10. Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004;50:3296-305.
11. Wolfe F, van ader Heijde DM, Larsen A. Assessing radiographic status of rheumatoid arthritis: introduction of a short erosion scale. J Rheumatol 2000;27:2090-9.
12. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982-9.
13. Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 2005;32:1006-12.
14. Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 2005;32:1261-6.
15. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5.
16. Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM health assessment questionnaire. J Rheumatol 2000;27:1989-99.
17. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30:369-78.
18. Wolfe F, Petri M, Alarcon GS et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009;36:82-8.
19. Pons-Estel B, Sánchez-Guerrero J, Romero-Díaz J et al. Validation of the Spanish, Portuguese and French versions of the lupus damage index questionnaire: data from North and South America, Spain and Portugal. Lupus 2009;18: 1033-52.
20. Costenbader KH, Khamashta M, Ruiz-Garcia S et al. Development and initial validation of the self-assessed Lupus Damage Index Questionnaire (LDIQ). Arthritis Care Res 2010;62:559-68.
21. Wolfe F, Kong SX. Rasch analysis of the Western Ontario MacMaster questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Ann Rheum Dis 1999;58:563-8.
22. Wolfe F, Michaud K, Kahler K, Omar M. The short arthritis assessment scale: a brief assessment questionnaire for rapid evaluation of arthritis severity in research and clinical practice. J Rheumatol 2004;31:2472-9.
23. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007; 57:935-42.
24. Shaver TS, Anderson JD, Weidensaul DN et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35: 1015-22.
25. Wolfe F, Clauw D, Fitzcharles MA. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10.
26. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
27. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biological therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:835-47.
28. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50: 1740-51.
29. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372-9.
30. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612-21.
31. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
32. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
33. Wolfe F, Michaud K. Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. J Rheumatol 2008;35:1023-30.
34. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
35. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000;27:1668-73.
36. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate therapy and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-7.
37. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
38. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004;31:695-700.
39. Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol 2009;36:831-6.
40. Hawley DJ, Wolfe F, Lue FA, Moldofsky H. Seasonal symptom severity in patients with rheumatic diseases: a study of 1,424 patients. J Rheumatol 2001;28:1900-9.
41. Wells GA, Boers M, Shea B et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
42. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010; 12:R35.
43. Bergman MJ, Shahouri SS, Shaver TS et al. Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue, osteoarthritis, and fibromyalgia. J Rheumatol 2009;36:2788-94.
44. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology 1999;38:355-61.
45. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
46. Allaire S, Wolfe F, Niu J, LaValley M, Michaud K. Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005;53: 603-8.
47. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83.
48. Dewitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006;166:57-63.
49. Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol 2007;34:1674-83.
50. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007;56:2135-42.